Literature DB >> 12297856

Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C.

Yuki Terui, Takafumi Saito, Hisayoshi Watanabe, Hitoshi Togashi, Sumio Kawata, Yoshihiro Kamada, Shigeru Sakuta.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12297856     DOI： 10.1053/jhep.2002.32679

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  33 in total

1.  Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: a pilot study.

Authors:  Silvia Sookoian; María Alejandra Fernández; Gustavo Castaño
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

2.  Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis.

Authors:  Shiro Yokohama; Yoshihiko Tokusashi; Kimihide Nakamura; Yosui Tamaki; Satoshi Okamoto; Mituyoshi Okada; Kazunobu Aso; Takenao Hasegawa; Masaru Aoshima; Naoyuki Miyokawa; Masakazu Haneda; Masashi Yoneda
Journal:  World J Gastroenterol       Date:  2006-01-14       Impact factor: 5.742

Review 3.  Renin-angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic review.

Authors:  Gaeun Kim; Juyoung Kim; Yoo Li Lim; Moon Young Kim; Soon Koo Baik
Journal:  Hepatol Int       Date:  2016-02-22       Impact factor: 6.047

4.  Losartan may inhibit the progression of liver fibrosis in chronic HCV patients.

Authors:  Zakaria A Salama; Ahmed Sadek; Ahmed M Abdelhady; Samar Kamal Darweesh; Shereif Ahmed Morsy; Gamal Esmat
Journal:  Hepatobiliary Surg Nutr       Date:  2016-06       Impact factor: 7.293

5.  ACE2 Therapy Using Adeno-associated Viral Vector Inhibits Liver Fibrosis in Mice.

Authors:  Kai Y Mak; Ruth Chin; Sharon C Cunningham; Miriam R Habib; Joseph Torresi; Alexandra F Sharland; Ian E Alexander; Peter W Angus; Chandana B Herath
Journal:  Mol Ther       Date:  2015-05-25       Impact factor: 11.454

Review 6.  Role of NADPH oxidases in liver fibrosis.

Authors:  Yong-Han Paik; Jonghwa Kim; Tomonori Aoyama; Samuele De Minicis; Ramon Bataller; David A Brenner
Journal:  Antioxid Redox Signal       Date:  2014-01-24       Impact factor: 8.401

Review 7.  Bioconjugation of oligonucleotides for treating liver fibrosis.

Authors:  Zhaoyang Ye; Houssam S Hajj Houssein; Ram I Mahato
Journal:  Oligonucleotides       Date:  2007

8.  Effect of propranolol on the splanchnic and peripheral renin angiotensin system in cirrhotic patients.

Authors:  Walkíria Wingester Vilas-Boas; Antônio Ribeiro-Oliveira; Renata da Cunha Ribeiro; Renata Lúcia Pereira Vieira; Jerusa Almeida; Ana Paula Nadu; Ana Cristina Simões e Silva; Robson Augusto Souza Santos
Journal:  World J Gastroenterol       Date:  2008-11-28       Impact factor: 5.742

9.  [Liver fibrosis : clinics, diagnostics and management].

Authors:  H E Wasmuth; C Trautwein
Journal:  Internist (Berl)       Date:  2010-01       Impact factor: 0.743

10.  Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment.

Authors:  Paschalis Paschos; Konstantinos Tziomalos
Journal:  World J Hepatol       Date:  2012-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.